Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

NCT00528073 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

410

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Rifaximin-EIR

Sponsor

Alfasigma S.p.A.